MAP2K1 and head and neck squamous cell carcinoma: While selumetinib is an effective, highly selective MEK1 inhibitor, trametinib has been shown to be active at sub-nanomolar concentrations against both purified MEK1 and MEK2 kinases, which may underlie its stronger effect on HNSCC-cell viability [19].